|
January 2012
|
-
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate
efficacy in the treatment of patients with
rheumatoid arthritis in a randomized, double-blind placebo-controlled
trial.
Fleishaker DL, Garcia Meijide JA,
et al
Arthritis Res Ther. 2012 Jan
17;14(1):R11.
-
Novel agents for the treatment of HIV-2 infection.
Peterson K, Rowland-Jones S.
Antivir Ther.
2012 Jan 25.
-
Responses to Switching to Maraviroc-Based Antiretroviral Therapy in
Treated Patients with
Suppressed Plasma HIV-1-RNA Load.
Vitiello P, Brudney D, Maccartney M,
et alIntervirology.
2012;55(2):172-8
-
A WEEK-IN-REVIEW FEATURED REPORT
Lack of short-term increase in serum mediators of fibrogenesis and in
non-invasive markers of liver fibrosis in
HIV/hepatitis C virus-coinfected patients starting maraviroc-based
antiretroviral therapy.
Macías J, Viloria MM, Rivero A, et al
Eur J Clin Microbiol Infect Dis.
2012 Jan 19.
-
Immunologic Effectiveness of Maraviroc- and Raltegravir-Containing
Regimens (R+M+) versus
Raltegravir-Based Regimens That Do Not Include Maraviroc (R+M-). Antoniou T, Smith G, Su D, et al
J Int Assoc Physicians AIDS Care (Chic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|